Targets › TPH1
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 3; Neurology, Oncology; next expected readout Dec 2026.
Oxidizes L-tryptophan to 5-hydroxy-l-tryptophan in the rate-determining step of serotonin biosynthesis. (UniProt, P17752)
Open in Phaseline: the race on TPH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| M.D. Anderson Cancer Center | Telotristat Ethyl Tryptophan 5-hydroxylase inhibitor | TPH2, TPH1 | Phase 3 | Locally Advanced Neuroendocrine Neoplasm | Aug 2028 |
| University of Alberta | 5-Hydroxytryptophan Serotonin precursor; converted to serotonin by aromatic L-amino acid decarboxylase | TPH1, TPH2 | Phase 2 | Spinal Cord Injuries | Dec 2026 |
Spinal Cord Injuries (1) Locally Advanced Neuroendocrine Neoplasm (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.